Vivos Therapeutics, Inc.
VVOS
$0.80
$0.022.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.82M | 6.78M | 3.82M | 3.02M | 3.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.82M | 6.78M | 3.82M | 3.02M | 3.70M |
| Cost of Revenue | 836.00K | 2.85M | 1.71M | 1.51M | 1.60M |
| Gross Profit | 2.99M | 3.94M | 2.11M | 1.51M | 2.10M |
| SG&A Expenses | 8.93M | 8.29M | 6.67M | 5.25M | 4.76M |
| Depreciation & Amortization | 442.00K | 384.00K | 306.00K | 177.00K | 144.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.21M | 11.52M | 8.69M | 6.93M | 6.50M |
| Operating Income | -6.38M | -4.73M | -4.87M | -3.92M | -2.81M |
| Income Before Tax | -6.95M | -5.40M | -5.01M | -3.86M | -2.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.95M | -5.40M | -5.01M | -3.86M | -2.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 60.00K | -- | -- | -- | -- |
| Net Income | -6.89M | -5.40M | -5.01M | -3.86M | -2.83M |
| EBIT | -6.38M | -4.73M | -4.87M | -3.92M | -2.81M |
| EBITDA | -5.94M | -4.35M | -4.56M | -3.74M | -2.66M |
| EPS Basic | -0.55 | -0.49 | -0.55 | -0.45 | -0.39 |
| Normalized Basic EPS | -0.35 | -0.31 | -0.34 | -0.28 | -0.24 |
| EPS Diluted | -0.55 | -0.49 | -0.55 | -0.45 | -0.39 |
| Normalized Diluted EPS | -0.35 | -0.31 | -0.34 | -0.28 | -0.24 |
| Average Basic Shares Outstanding | 12.42M | 10.96M | 9.09M | 8.60M | 7.23M |
| Average Diluted Shares Outstanding | 12.42M | 10.96M | 9.09M | 8.60M | 7.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |